Neoplasms — Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)
Citation(s)
An Open-Label Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) in Patients With CD30-Positive Hematologic Malignancies: CYP3A4 Drug-Drug Interactions, Excretion, and Special Populations